# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Abbott faces trial over claims its baby formula causes necrotizing enterocolitis in preterm infants. This is the second trial a...
Evercore ISI Group analyst Vijay Kumar maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price targe...
- Reuters
WuXi AppTec employees collaborated with China's PLA on altitude sickness drugs, raising national security concerns in the U...